FDA Review Begins for Shionogi’s Pediatric Use of Fetroja Antibiotic
Event summary
- FDA accepted Shionogi’s sNDA for Fetroja to treat pediatric patients with serious Gram-negative bacterial infections.
- Action date set for February 23, 2027 under PDUFA.
- sNDA supported by three clinical studies involving 154 children from birth to <18 years old.
- Fetroja is already approved for adult patients with cUTI and HABP/VABP.
The big picture
Shionogi’s FDA filing represents a strategic push to address unmet medical needs in pediatric infectious disease, particularly as antimicrobial resistance grows. The company’s collaboration with BARDA and inclusion on WHO’s PAedo Drug Optimization priority list underscores the critical need for effective treatments in this vulnerable population.
What we're watching
- Regulatory Timing
- Whether the FDA will meet the February 2027 PDUFA action date for pediatric approval.
- Market Expansion
- How successful Shionogi will be in expanding Fetroja’s use into pediatric populations globally.
- Competitive Dynamics
- The pace at which competitors develop similar pediatric antibiotics for Gram-negative infections.
Related topics